Table 4.
Univariate Analysis for Factors Associated With Development of HCC
| No HCC | HCC | P Value | |
|---|---|---|---|
| Mean age, yr | 46.9 ± 14.9 | 57.4 ± 14.8 | .0002 |
| Male, n | 254/369 (68.8%) | 28/31 (90.3%) | .006 |
| Asian, n | 288/369 (78.0%) | 26/31 (83.9%) | .002 |
| Mean albumin, mg/dL | 4.16 ± 0.58 | 3.62 ± 1.02 | <.0001 |
| Mean AST, U/L | 42.4 ± 62.9 | 50.9 ± 24.3 | .46 |
| Mean ALT, U/L | 53.6 ± 66.2 | 51.1 ± 22.9 | .84 |
| Mean bilirubin, mg/dL | 0.59 ± 0.48 | 0.74 ± 0.65 | .11 |
| Mean platelets, × 103/mm3 | 158.5 ± 107.8 | 101.7 ± 89.7 | .008 |
| HBeAg-positive, n/total | 185/197 (93.9%) | 12/197 (6.1%) | .26 |
| Anti-HBe, n/total | 170/189 (89.9%) | 19/189 (10.1%) | .11 |
| Inactive carriers, n/total | 110/110 (100%) | 0/110 (0%) | - |
| Chronic hepatitis, n/total | 142/151 (94.0%) | 9/151 (6.0%) | - |
| Cirrhosis, n/total | 117/139 (84.2%) | 22/139 (15.8%) | <.0001 |
ALT = alanine aminotransferase; anti-BHe = antibodies to HBeAg; AST = aspartate aminotransferase; HBeAg = hepatitis B early antigen; HCC = hepatocellular carcinoma.